Endometrial Cancer Trial, Recruiting NCT06680791 Sponsor: Lukas Vanek Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06680791
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with endometrial cancer (cancer of the lining of the uterus).
  • People who have had surgery to remove the uterus, along with appropriate procedures to determine the stage of the cancer.

Who may not be able to join:

  • There are no exclusion criteria listed for this trial — no specific groups are stated to be ineligible.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Halaška, prof. MUDr., Medical director

Phone: +420 296472368

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lukas Vanek
Registry
ClinicalTrials.gov
Start date
15 July 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

Genetic variants/mutation signatures; Quality of life of EC patients using the EORTC QLQ-C30 questionnaire; Quality of life of EC patients using the EORTC QLQ-EN24 questionnaire; Physical activity of EC patients; Introduction of methodology of ctDNA detection by digital PCR of consecutive follow-up samples.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov